Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

New Stocks Added to the Biotech Directories : Camp4 Therapeutics Corp (Nasdaq:CAMP ) is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein ...

Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

Camp4 Therapeutics (CAMP) stock gains after J.P. Morgan and Piper Sandler launched its coverage with Overweight ...

Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. In this episode, host Fraser Palamara dissects the $6 million raising completed today by biotech ...

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive ...

DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new ...